(1S,2S)-1,2-Bis(4-methoxyphenyl)ethylenediamine dihydrochloride

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 英文名称: (1S,2S)-1,2-Bis(4-methoxyphenyl)ethylenediamine dihydrochloride
• 英文别名: 1,2-bis(4-methoxyphenyl)ethane-1,2-diamine;dihydrochloride
• 化学式: C16H22Cl2N2O2
• 分子量: 345.3
• InChiKey: XOCFEHGXXCSIDO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.25
• 重原子数：
  22
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  70.5
• 氢给体数：
  4
• 氢受体数：
  4

文献信息

• [EN] PROCESSES FOR PREPARING ACC INHIBITORS AND SOLID FORMS THEREOF<br/>[FR] PROCÉDÉS DE PRÉPARATION D'INHIBITEURS D'ACC ET FORMES SOLIDES CORRESPONDANTES
  申请人：GILEAD SCIENCES INC

  公开号：WO2018161022A1

  公开（公告）日：2018-09-07

  The present disclosure provides solid forms, including a salt or co-crystal, of Compound I which exhibits Acetyl-CoA carboxylase ("ACC") inhibitory activity and may be useful in treating ACC mediated diseases. Also provided herein are processes or steps for the preparation of a Compound I and intermediates useful for the processes or steps described herein.

  本公开提供了化合物I的固体形式，包括盐或共晶，该化合物表现出乙酰辅酶A羧化酶（"ACC"）抑制活性，并可能在治疗ACC介导的疾病中有用。本文还提供了用于制备化合物I的过程或步骤，以及对所述过程或步骤有用的中间体。
• Processes for preparing ACC inhibitors and solid forms thereof
  申请人：Gilead Sciences, Inc.

  公开号：US10745412B2

  公开（公告）日：2020-08-18

  The present disclosure provides solid forms, including a salt or co-crystal, of Compound I: which exhibits Acetyl-CoA carboxylase (“ACC”) inhibitory activity and may be useful in treating ACC mediated diseases. Also provided herein are processes or steps for the preparation of a Compound I and intermediates useful for the processes or steps described herein.

  本公开提供了化合物 I 的固体形式，包括盐或共晶体： 化合物 I 具有乙酰-CoA 羧化酶（"ACC"）抑制活性，可用于治疗 ACC 介导的疾病。本文还提供了制备化合物 I 的工艺或步骤以及用于本文所述工艺或步骤的中间体。
• PROCESSES FOR PREPARING ACC INHIBITORS AND SOLID FORMS THEREOF
  申请人：Gilead Sciences, Inc.

  公开号：US20180298025A1

  公开（公告）日：2018-10-18

  The present disclosure provides solid forms, including a salt or co-crystal, of Compound I: which exhibits Acetyl-CoA carboxylase (“ACC”) inhibitory activity and may be useful in treating ACC mediated diseases. Also provided herein are processes or steps for the preparation of a Compound I and intermediates useful for the processes or steps described herein.